Pancreatic Ductal Adenocarcinoma study: Lumason vs Contrast-Enhanced Ultrasound
Official title The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence
ClinicalTrials.gov ID: NCT07910383
What this study is testing
What is Lumason?
Lumason is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for pancreatic ductal adenocarcinoma.
Also referred to as sulfur hexafluoride lipid-type A microspheres.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether a special type of ultrasound called contrast-enhanced ultrasound (CEUS) can help detect if pancreatic cancer has come back after surgery.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Be a patient that underwent surgical resection of PDAC located in the head or body of the pancreas and are being followed for recurrence with CT...
- Be 18 years of age or older.
- If the subject is of child-bearing potential, must have a negative pregnancy test.
- Be conscious and able to comply with study procedures.
- Have read and signed the IRB approved consent form for participating in the study.
You likely can't join if
- Females who are pregnant or nursing.
- Patients who have received an investigational drug in the 30 days before study drug administration or will receive one within 72 hours afterwards.
- Patients on life support or in a critical care unit.
- Patients with clinically unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable...
- Patients with recent cerebral hemorrhage (within 1 month).
- Patients who have undergone surgery within 24 hours prior to the study ultrasound imaging examination.
See the full eligibility criteria
- Be a patient that underwent surgical resection of PDAC located in the head or body of the pancreas and are being followed for recurrence with CT imaging as part of their standard of care.
- Be 18 years of age or older.
- If the subject is of child-bearing potential, must have a negative pregnancy test.
- Be conscious and able to comply with study procedures.
- Have read and signed the IRB approved consent form for participating in the study.
- Females who are pregnant or nursing.
- Patients who have received an investigational drug in the 30 days before study drug administration or will receive one within 72 hours afterwards.
- Patients on life support or in a critical care unit.
- Patients with clinically unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)
- Patients with recent cerebral hemorrhage (within 1 month).
- Patients who have undergone surgery within 24 hours prior to the study ultrasound imaging examination.
- Patients with congenital heart defects.
- Patient with a known allergy to Lumason.
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.